100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant

BACKGROUND: Measles, mumps and rubella (MMR) vaccine is a live-attenuated vaccine usually contraindicated within the first two years of hematopoietic cell transplant (HCT). During the 2019 measles outbreak at our center, the benefits of administering MMR vaccine within the first two years after HCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitre, Xhoi, Feeley, Monica, Sherman, Amy C, Walsh, Stephen R, Cheng, Matthew, Kanjilal, Sanjat, Ho, Vincent T, Baden, Lindsey R, Issa, Nicolas C, Desjardins, Michaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644540/
http://dx.doi.org/10.1093/ofid/ofab466.100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644540/
http://dx.doi.org/10.1093/ofid/ofab466.100

Ejemplares similares